Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Rhabdomyosarcoma to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Rhabdomyosarcoma to Oncology Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Rhabdomyosarcoma Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Rhabdomyosarcoma 35
May 09, 2018: Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma 35
Clinical Trial Profile Snapshots 36
Appendix 221
Abbreviations 221
Definitions 221
Research Methodology 222
Secondary Research 222
About GlobalData 223
Contact Us 223
Disclaimer 223
Source 223

List of Tables
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region, 2018* 7
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2018* 20
Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase, 2018* 23
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 24
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 27
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 28
Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 29
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 34

List of Figures
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2018* 20
Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 23
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 24
Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 27
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 28
Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 29
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 30
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 32
Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 34
GlobalData Methodology 222

Companies Mentioned
- Eli Lilly and Co
- Novartis AG
- Pfizer Inc
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd
- Eisai Co Ltd
- Children’s Healthcare of Atlanta Inc
- C. H. Boehringer Sohn AG & Co KG
- Bayer AG
- AstraZeneca Plc